19,568 Shares in Anavex Life Sciences Corp. (NASDAQ:AVXL) Purchased by Fox Run Management L.L.C.

Fox Run Management L.L.C. purchased a new stake in shares of Anavex Life Sciences Corp. (NASDAQ:AVXL) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 19,568 shares of the biotechnology company’s stock, valued at approximately $210,000.

Other large investors also recently bought and sold shares of the company. Essential Planning LLC. purchased a new position in shares of Anavex Life Sciences during the 4th quarter valued at approximately $4,437,000. Virtu Financial LLC purchased a new position in Anavex Life Sciences in the fourth quarter valued at $967,000. Barclays PLC raised its position in shares of Anavex Life Sciences by 70.4% in the third quarter. Barclays PLC now owns 155,179 shares of the biotechnology company’s stock worth $882,000 after acquiring an additional 64,101 shares during the period. Geode Capital Management LLC boosted its stake in shares of Anavex Life Sciences by 2.8% during the 3rd quarter. Geode Capital Management LLC now owns 1,883,199 shares of the biotechnology company’s stock worth $10,699,000 after acquiring an additional 51,946 shares in the last quarter. Finally, Atria Wealth Solutions Inc. acquired a new stake in shares of Anavex Life Sciences during the 4th quarter valued at about $291,000. 31.55% of the stock is owned by institutional investors and hedge funds.

Anavex Life Sciences Stock Performance

Anavex Life Sciences stock opened at $8.72 on Friday. The company’s 50 day simple moving average is $9.01 and its 200-day simple moving average is $8.28. Anavex Life Sciences Corp. has a 1 year low of $3.25 and a 1 year high of $14.44. The company has a market capitalization of $741.76 million, a price-to-earnings ratio of -15.85 and a beta of 0.94.

Anavex Life Sciences (NASDAQ:AVXL) last announced its earnings results on Wednesday, February 12th. The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.03. Equities analysts expect that Anavex Life Sciences Corp. will post -0.69 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on AVXL shares. HC Wainwright reaffirmed a “buy” rating and set a $42.00 price objective on shares of Anavex Life Sciences in a report on Tuesday, February 18th. D. Boral Capital reissued a “buy” rating and set a $46.00 price target on shares of Anavex Life Sciences in a research report on Wednesday, February 12th.

About Anavex Life Sciences

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.